Background: Human leukocyte antigen (HLA) phenotype is a prognostic marker of cancer
immunotherapy, and the expression profile of its alleles is associated with therapeutic rate …

7043 Background: We prospectively studied BCR-ABL transcript type (b2a2, b3a2, e1a2
and e19a2 in 100 CML-CP patients treated with Imatinib mesylate therapy and studied their …

We conducted this study to identify the factors for predicting poor outcomes in chronic
myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR) …

Prognostic factors which can predict response to imatinib in patients with chronic myeloid
leukemia (CML) have been of much interest. Identification of patients who are likely to fail to …

Abstract 2790 The approval of second-generation tyrosine kinase inhibitors (TKIs) for the
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …

Objectives Achieving a major molecular response (MMR) is the goal of imatinib therapy for
chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …

Abstract Abstract 1680 We studied BCR-ABL1 transcript levels in patients with CML in
chronic phase at 3, 6 and 12 months after starting imatinib to identify molecular milestones …

Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase
chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early …

The approval of three tyrosine kinase inhibitors (TKIs) for the first line treatment of Chronic
Myeloid Leukemia (CML) has generated an urgent need for molecular parameters predictive …